- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Nemaura Publishes Positive Data from SugarBEAT FDA Clinical Trial
Nemaura Medical (NASDAQ:NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by people with diabetes and pre-diabetics, today published clinical data from its recently completed study intended to support a De Novo submission to the U.S Food & Drug Administration (“FDA”) for approval of its …
Nemaura Medical (NASDAQ:NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by people with diabetes and pre-diabetics, today published clinical data from its recently completed study intended to support a De Novo submission to the U.S Food & Drug Administration (“FDA”) for approval of its sugarBEAT® product.
As quoted in the press release:
The global addressable market for CGM is estimated at $82B per annum, with the U.S. the largest single market estimated at $13B. CGM adoption amongst people with diabetes is minimal and growing rapidly, with the U.S. having an estimated 2.6% (630,000 users) of all diagnosed diabetics using CGM in 2018, representing annualized growth of 117%.(1)
The results from the recently completed clinical study consisted of 75 patients, split approximately equally between Type I and Type II diabetics. Blood samples were taken via a catheter every 15 minutes over a 12 hour period for 3 non-consecutive days, for a total of 225 patient days, and measured using an Architect c8000 Laboratory Instrument.(2)
Over 12,000 paired data points were analysed using 1-point and 2-point calibration respectively, using a predictive algorithm. MARD +/-20% or +/- 20mg/dL (76% of paired data) was 8.02% for the single finger prick calibration and 7.96% (78.7% of all data) for the 2-point calibration.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.